Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000592581 | SCV000704258 | uncertain significance | not provided | 2016-12-20 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000696116 | SCV000824664 | likely pathogenic | Charcot-Marie-Tooth disease type 2 | 2022-02-25 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 498978). This missense change has been observed in individual(s) with a clinical presentation consistent with a laminopathy (Invitae). In at least one individual the variant was observed to be de novo. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 372 of the LMNA protein (p.Glu372Lys). |
Revvity Omics, |
RCV000592581 | SCV003814739 | uncertain significance | not provided | 2019-03-14 | criteria provided, single submitter | clinical testing |